80,000+
Men with prostate cancer
could ultimately benefit from CCS1477 annually
20,000+
Patients with blood cancers
multiple myeloma, AML, lymphomas
50+
Epigenetic-related targets
investigated over time by the CellCentric team
1
Drug prioritised, advanced
CCS1477 in the clinic, for multiple indications
The science
There is a large and growing population of prostate cancer patients that are resistant to second generation anti-hormonal drugs (Xtandi, Zytiga, Erleada). CCS1477 addresses this through targeting the key drivers of resistance and late stage disease; the androgen receptor (AR), AR splice variants (AR-SV) and c-Myc.
Other cancer tumours are also susceptible to p300/CBP inhibition, notably specific haematological cancers; multiple myeloma, acute myeloid leukaemia (AML) and certain lymphomas.
Backed by strong pre-clinical data, CCS1477 is now being trialed in patients.
The company is supported by a strong network of clinical, scientific and commercial advisors. CellCentric also actively collaborates with a number of world-leading cancer research centres on the effects of CCS1477 and p300/CBP inhibition.
CCS1477 inhibits p300/CBP. Clinical trial for late stage prostate ongoing; haem cancers to follow. pic.twitter.com/jQFekuLq5J
Tim’s collaborative research helped steer CCS1477 for AML. Now heading to the clinic together. pic.twitter.com/lWBDRdMHUS
p300/CBP inhibition impacts IRF4-Myc. CellCentric’s CCS1477 to be tested clinically for haem cancers. pic.twitter.com/aucIY4ZHEc